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“Success isn’t a result of spontaneous combustion. You must set yourself on fire”                   
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ABSTRACT 
Ductal adenocarcinoma of the prostate (DAC) is the second most common prostate cancer 
subtype. Patients with DAC often present at an advanced clinicopathological stage, with or 
without metastases. Patients have a high rate of extraprostatic extension, seminal vesicle 
invasion, a shortened time to biochemical recurrence as well as regional and distant 
metastases. The diagnosis of DAC continues to challenge pathologists half a century after its 
discovery. Histologically, DAC is an adenocarcinoma with papillary, cribriform, glandular or 
mixed architecture. The epithelium is tall, columnar, pseudostratified and the nuclei 
elongated with high-grade features. Our aim was to characterize the entity of DAC by 
morphology, immunohistochemistry and genetic analyses to provide better understanding and 
tools for diagnosis.  
The prognostic significance of histopathological features of DAC were analyzed. Classic 
DAC shows tall, columnar, pseudostratified epithelium, elongated nuclei and papillary, 
glandular and/or cribriform architecture. The tumors may lack elongated nuclei or classical 
architecture and still have similar prognosis, which justifies their classification as DAC. 
However, cases with only stratified, high grade nuclei had better prognosis and should not be 
considered DAC. The reproducibility of the DAC diagnosis was evaluated among 
international experts on prostate pathology. The most useful diagnostic feature of DAC was 
papillary architecture while nuclear and cellular features were less important. The most 
common differential diagnoses to DAC included intraductal prostate cancer, acinar 
adenocarcinoma and high-grade PIN. The immunohistochemical profile of DAC showed 
overlap with staining patterns of acinar adenocarcinomas, but differences consistent with the 
more aggressive phenotype of DAC were noted, such as a higher expression of Ki-67, p53 
and p16. The immunohistochemical profile of DAC was also compared with that of 
adenocarcinomas of non-prostatic origin. To diagnose the site of origin of metastases may be 
challenging as DAC resembles some other adenocarcinomas morphologically. The 
expression of cytokeratins and intestinal markers in DAC were not specific and may lead to 
diagnostic errors if not combined with prostate specific markers. In men with 
adenocarcinoma of unknown primary, the threshold for applying prostate specific 
immunomarkers should be low even when the morphology suggests a non-prostatic origin. 
The genetic profile of DAC was analyzed by sequencing and was found to be similar to that 
of advanced and/or metastatic acinar adenocarcinoma of the prostate. This can explain the 
aggressive behavior of this prostate cancer subtype and may also offer targets for future 
tailored therapies. 
  
 
  
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Prostatacancer är den vanligaste cancerformen i Sverige, under 2011 diagnostiserades 9 663 
män i Sverige med sjukdomen. I dagsläget har cirka 20 olika typer av prostatacancer 
beskrivits. Den vanligaste varianten kallas för acinärt adenocarcinom och står för dryga 90 % 
av alla fall, medan den näst vanligaste varianten kallas för duktalt adenocarcinom och 
beskrevs för första gången på 1950-talet. När man tittar på tumörerna i mikroskop skiljer sig 
den duktala cancern jämfört med den acinära. Duktal cancer har har avlånga celler som ser ut 
att vara ordnade i flera lager, arkitekturen är oftast papillär eller kribriform men man kan se 
en blandning av båda dessa typer. Patienter som drabbas av duktalt adenocarcinom har en 
sämre prognos än de som drabbas av acinärt adenocarcinom men man har inte kunnat 
förklara varför. Trots att prostatan ofta opereras bort hos dessa patienter har man sett att 
duktal cancer ofta växer utanför prostatan, att all tumörvävnad inte är borttagen vid 
operationen och att de ofta har spridning av tumören till andra vävnader i kroppen. Vårt mål 
var att kartlägga duktal cancer och definiera diagnoskriterier, kartlägga dess mikroskopiska 
utseende och jämföra såväl proteinuttryck som genetiska skillnader mellan duktalt och acinärt 
adenocarcinom.  
Vi kom fram till att den duktala cancern oftast växer tillsammans med en acinär cancer som i 
de flesta fall är elakartad. Tumören återfinns oftast i de perifera delarna av prostatan och hos 
de patienter där man opererar bort prostatan ser man i större utsträckning att tumören växer 
utanför prostatan, in i sädesblåsorna och att det ofta finns cancerceller kvar i området efter 
operationen. Det drag som är mest användbart för att ställa diagnosen duktal cancer är den 
papillära arkitekturen. Brist på typisk arkitektur är oftast anledningen till att patologer inte 
ställer diagnosen. Det finns flera olika typer av prostatacancer som kan misstas för duktalt 
adenocarcinom. 
När vi undersökte proteinuttrycket visade det sig att duktal cancer oftare uttrycker proteiner 
som talar för en aggressiv cancer. Duktal cancer kan likna cancer från andra organ såsom 
bukspottkörtel, lunga, magsäck, tjocktarm eller urinblåsa. Detta gör att det kan vara svårt att 
avgöra om cancerceller man finner i andra delar av kroppen, så kallade metastaser, kommer 
från prostatan eller något annat organ. För att säkerställa att det rör sig om ett duktalt 
adenocarcinom bör man därför titta på proteiner som är specifika för prostatan då detta ökar 
chansen att ställa rätt diagnos. På DNA-nivå kunde vi se att duktalt adenocarcinom uppvisar 
förändringar som förekommer i avancerad och/eller metastaserad prostatacancer. 
Sammanfattningsvis är duktal cancer en aggressiv subtyp med förändringar i såväl 
proteinuttryck som på gennivå vilka kan förklara dess aggressiva beteende.  
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1 INTRODUCTION 
 
1.1 PROSTATE CANCER IN SWEDEN 
“Declare the past, diagnose the present, foretell the future” 
     —Hippocrates 
Prostate cancer is the most common cancer in Sweden where it accounts for one third of all 
cancers in men. In 2011, 9 663 men were diagnosed with prostate cancer and together they 
accounted for nearly a third (32.2 %) of all newly diagnosed cancers. Uncommon before 50 
years of age, only 85 men under the age of 50 were diagnosed with the disease in 2011. The 
5-year survival is 91.6 % and a majority of patients eventually die of unrelated causes such as 
acute myocardial infarction or stroke. Nevertheless, prostate cancer is a heterogeneous 
disease with some patients living with indolent disease for decades while others present with 
metastases and a short overall survival (1).  
The diagnosis is based on analysis of serum prostate-specific antigen (s-PSA), digital rectal 
examination and histopathologic examination of core biopsies acquired through transrectal 
ultrasound. In some patients magnetic resonance imaging (MRI) is performed. s-PSA levels 
may be elevated due to other causes than prostate cancer such as a urinary infection, 
prostatitis or benign prostatic hyperplasia. There is no national s-PSA screening program in 
Sweden but many men ask for the test at primary health care centers and s-PSA testing has 
increased during the last decade. However, the false-positive rate of s-PSA is high, which 
leads to unnecessary prostate biopsies and ultimately over-diagnosis of low-risk prostate 
cancers. Nevertheless, efforts are being made to improve the sensitivity and specificity of the 
diagnosis of prostate cancer. A recent study described a new model to reduce unnecessary 
biopsies without diagnosing less prostate cancers with a Gleason score (GS) of at least 7. This 
was achieved by combining plasma protein biomarkers and genetic polymorphisms. Clinical 
variables included age, family history, previous prostate biopsy and/or exam. s-PSA 
concentration was tested in all participants (2). Hence, in the near future, evaluation of a 
combination of variables may be the gold standard in daily clinical work.  
Approximately 50 % of the patients diagnosed with prostate cancer are treated with radiation 
therapy, surgery or a combination. Radiation therapy may also be combined with hormonal 
treatment to reduce tumor burden prior to treatment. Patients with tumors of low GS may be 
subjected to active surveillance, where s-PSA and core biopsies are analyzed at certain time 
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intervals. Patients with metastasized disease at time of diagnosis may be subjected to surgical 
or chemical castration as well as chemotherapy. An estimated 25 % of patients suffer 
biochemical recurrence, i.e. a rising s-PSA after surgical treatment or radiation therapy (1). 
1.2 PROSTATE CANCER GLOBALLY 
An autopsy study by Franks in 1954 (3) revealed prostate cancer to be more common than 
previously thought. Franks identified 69 prostate carcinomas at autopsies of 220 patients, 
none of the cancers had been diagnosed before death and in none of the men were they the 
cause of death. Franks also demonstrated that prostate cancer is correlated to age: in the age 
group 60-79 years prostate cancer was found in approximately one third of patients, in the 
age group 80-89 years in almost 50 %, 90-99 years 75 % and in patients over 100 years old, 
all patients had prostate cancer. One could assume that these were all indolent, well-defined 
tumors, however, 20 % showed large, anaplastic areas.  
Prostate cancer is the second most common cancer among men globally and the fourth most 
common cancer in both sexes combined (4). One point one million men were diagnosed with 
prostate cancer in 2012, accounting for 15 % of all cancers diagnosed in men. Of these, 70 % 
occurred in countries such as Australia, New Zealand and North America as well as Western 
and Northern parts of Europe where the incidence is high Figure 1. The incidence is high also 
in less developed regions including the Caribbean, Southern parts of Africa and South 
America while it is less common in Asia. In 2012, 307 000 men died of their prostate cancer 
globally, making it the fifth most common cause of cancer related death. The mortality rates 
are highest in black populations (4). The high incidence of prostate cancer is partly because s-
PSA testing and core biopsies are common diagnostic tools in developed regions. The use of 
s-PSA dates back 30 years in high-income countries and has led to a higher incidence of 
prostate cancer as the detection rate increases. In 2001, 75 % of American males over 50 
years of age had been subjected to s-PSA testing (5). In summary, the incidence of prostate 
cancer is largely dependent on the efforts to detect the disease. Some risk factors have been 
identified and include age, black race, family history of prostate cancer and certain genetic 
traits (6).  
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Figure 1 The incidence of prostate cancer in Europe. As can be seen, the incidence is high in the Nordic 
countries. Reprinted from http://eco.iarc.fr/eucan 
1.3 PERSONALIZED PROSTATE CANCER MEDICINE? 
“It is more important to know what sort of person has a disease than to know what sort of 
disease a person has”     —Hippocrates 
It is known that there are several molecular subtypes of cancer and that we are entering an era 
where treatment for each individual patient may be based on the unique tumor signature and 
not only tissue origin or anatomical site. A normal cell develops into a cancer cell by 
accumulating genetic changes, which may be acquired sporadically or through inheritance. 
Inherited genetic changes allow clinicians to identify patients at risk of developing a certain 
cancer type and provide treatment and recommend life style changes (7). For example, the 
BRCA1 and BRCA2 genes can be identified and patients subjected to early treatment to 
prevent death from breast cancer. Prostate cancer is the most common cancer among men in 
the Western world but better predictors of individual treatment response are needed to 
provide customized treatment. There is currently a risk of over treatment of patients with 
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indolent and low-risk disease where patients are put at unnecessary risk of post-radiation or 
post-surgical complications.  
Prostate cancer treatment today is generally not based on the histological subtype or genetic 
signature but the TNM system where T-category, s-PSA and GS stratifies the patients into 
low, intermediate and high risk groups, predicting the risk of biochemical recurrence (8) 
Figure 2. For patients with low-risk disease, active surveillance may be sufficient. However, 
the patient may wish to be treated with radiation therapy or radical prostatectomy (RP), 
treatment decision thus being a combination of tumor biology and the patient’s wish. If 
histological review shows positive surgical margins or extraprostatic extension (EPE), 
patients may benefit from radiotherapy (9). Those with high-risk prostate cancer benefit from 
RP or radiation therapy followed by androgen deprivation therapy. Despite treatment some 
patients develop metastatic disease and palliative disease is then managed by chemotherapy, 
androgen deprivation, radiation or secondary hormonal treatment. There are currently no tests 
to tell who will benefit from single or combination therapy. The lack of predictors of 
treatment outcome and prognosis makes personalized prostate cancer medicine challenging. 
Multifocality and interpatient as well as intrapatient heterogeneity in prostate cancer biopsies 
contribute to potential sampling bias. Despite the prognostic factors s-PSA, GS and T-stage, 
we cannot estimate a patients’ risk of developing aggressive disease and a deeper 
understanding of the tumor heterogeneity is needed before we can offer personalized 
treatment. Prostate cancer is a heterogeneous disease and several foci are typically seen in 
one patient together with several clonal subpopulations (10). Aggressive prostate cancers 
seeding metastases early or harboring local resistance to therapy would benefit from early 
detection such as genetic signatures predicting which patients to select for aggressive and 
immediate treatment. Presence of subtypes such as ductal adenocarcinoma of the prostate 
(DAC) may affect clinical outcome. It is already known that the subtype intraductal prostate 
cancer (IDC-P) is a risk factor for aggressive disease (11).  
Although GS allows for the identification and grading of separate foci, further subgrouping 
by genomic alterations could be of benefit in clinical practice, such as TMPRSS2ERG gene 
fusions, c-myc, PTEN and/or NKX3.1 status (12, 13). Genetic signatures in core needle or 
liquid biopsies may tell us if the patient will develop aggressive disease, before we send our 
patient to the operating theater or radiation therapy. In RP specimens with several tumor foci 
we must also be sure of which clone decides the outcome and why. Recent studies have 
aimed to evaluate expression signatures with estimated overall survival time and results could 
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hopefully be used in clinical diagnostics for optimal treatment decisions based on the survival 
benefit (14).  
 
Figure 2 The Gleason grading scale from least aggressive (1) to most aggressive (5). Adapted and reprinted with 
permission from The Prostate Cancer Foundation Australia  
1.4 HISTOLOGICAL SUBTYPES 
Today, 9 out of 10 patients are diagnosed with acinar adenocarcinoma while DAC is the 
second most common subtype. Other histological variants can be grouped into acinar and 
non-acinar carcinoma variants. Variants of acinar adenocarcinoma include atrophic, foamy, 
signet-ring, colloid, oncocytic, pseudohyperplastic and lymphoepithelioma-like 
adenocarcinomas. Non-acinar carcinomas include DAC, basal cell carcinoma, 
neuroendocrine tumors, squamous and adenosquamous adenocarcinoma, urothelial 
carcinoma and sarcomatoid carcinoma. Since the WHO 2004 classification several subtypes 
have emerged, such as pleomorphic giant cell carcinoma, large-cell neuroendocrine 
carcinoma, microcystic carcinoma and prostatic intraepithelial neoplasia-like adenocarcinoma 
(15). Some of them are extremely uncommon and rarely encountered in daily clinical work 
while others, such as DAC, are more common. The subtypes differ in clinical course as well 
as in histopathologic features and may be assigned different GS, hence correct identification 
and classification is important for patient management and outcome.  
1.5 THE STORY OF DAC 
1.5.1 The first case 
A 66-year-old man of previously good health is admitted to Parkway Hospital, New York in 
March 1966 due to a delay in onset of urination, nocturia and dribbling. Physical examination 
shows no abnormalities and the digital rectal examination reveals a firm but not nodular 
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prostate. The clinical impression is benign prostatic hyperplasia. Dr George Golding performs 
a suprapubic prostatectomy on March 8 1966, but what was thought to be a benign 
hyperplastic prostate turns out to be a prostate malignancy never seen before. The microacini 
are not arranged in a back-to-back fashion, in cribriform or solid areas but instead masses of 
columnar cells are seen, with the greatest concentration near the urethra. This is currently 
viewed as the first description of what would later be known as ductal adenocarcinoma of the 
prostate (16).  
DAC is known to have an adverse prognosis with shortened time to biochemical recurrence, 
increased mortality rate, short term failure rate after radical prostatectomy, positive surgical 
margins, EPE, seminal vesicle invasion (SVI) and positive pelvic lymph nodes (17-19). At 
the time of its discovery, DAC was thought to stem from a Müllerian duct remnant, hence a 
female tissue origin, due to its resemblance to endometrial adenocarcinoma (16). Although 50 
years have passed since the first description there are still controversies regarding diagnosis, 
patient management and outcome.  
1.6 EARLY DESCRIPTIONS OF DAC 
Ever since the first description DAC has been a source of conflict and debate. The tumor type 
has been referred to as endometrial carcinoma of the prostatic utricle, endometrial carcinoma 
of the prostate, adenocarcinoma with endometrioid features, primary prostatic duct 
adenocarcinoma as well as papillary carcinoma of the prostate, but is today commonly 
referred to as ductal adenocarcinoma of the prostate. 
The patient described by Melicow and Pachter is commonly considered to be the first 
reported patient with DAC (16). The microscopic appearance with a large volume of 
columnar cells arranged in bands with a pseudopapillary architecture led the authors to 
believe that the malignancy stemmed from the “uterus masculinus”. The rationale behind this 
was that the malignant cells were concentrated around the verumontanum, which is a 
structure in the dorsal wall of the urethra forming a conical elevation that protrudes into the 
urethral lumen. Located at the apex is a structure known as the utricle, described 400 years 
ago (20) Figure 3. This was earlier viewed as a Müllerian duct remnant, hence a tissue of 
female origin. It was even viewed by some as the male correspondence to the female vagina, 
hence the term “vagina masculina”. The thought that some of these female glands would 
persist and become neoplastically changed did not seem inconceivable (21).  
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Figure 3 The supposed origin of ductal adenocarcinoma of the prostate, the prostatic utricle. Reprinted from 
Anatomy of the Human Body, Henry Gray, 1918  
 
The Müllerian origin was to great extent based on an article by Glenister whom in 1962 
described the prostatic utricle arising at the site of merging of the urogenital sinus, 
mesonephric and paramesonephric ducts on the Müllerian tubercle, which later becomes the 
colliculus seminalis (22). The epithelium lining the cranial portion of the utricle is derived 
from the paramesonephric ducts while the caudal portion from the mixed epithelium, namely 
endodermal urogenital sinus cells, mesodermal Wolffian cells and the paramesonephric 
Müllerian cells, which also covers the colliculus seminalis or the verumontanum (22). An 
earlier study by Zondek et al. (23) also confirmed the utricle to be formed from the fused 
caudal ends of the Müllerian ducts, hence a supposed female tissue rest.  
More recent studies, however, support a resemblance to prostatic tissue derived from the 
urogenital sinus and not the Müllerian derived endometrial tissue (24). Wernert et al. (25) 
were the first to perform an immunohistochemical investigation of the utricle. They 
demonstrated a prostate-specific antigen (PSA) and prostate-specific acid phosphatase 
(PSAP) positivity of the utricle from the 5th month of life, as well as keratins, 
carcinoembryonic antigen (CEA) and peanut agglutinin. The positivity was similar to that of 
normal prostate glands, suggesting that the epithelium of the urogenital sinus participated in 
the lining of the utricle during embryogenesis. The debate was settled in 2004 when Shapiro 
et al. (26) proved the utricle to have its origin in the urogenital sinus. The authors used 
immunohistochemical biomarkers p63, uroplakins, vimentin, PAX-2 and Ki-67 to show that 
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male fetuses demonstrate a weak expression of p63 in the basal layer of the urogenital sinus 
around 9 weeks of gestation. At 11 weeks of gestation, the Müllerian ducts express PAX-2 
and p63 to some extent. Meanwhile, the p63 staining of the urogenital sinus increases. By 14-
15 weeks of gestation, the Müllerian ducts are undergoing apoptosis and uroplakin-
expressing epithelium grows into the periurethral stroma, forming a sheet of p63 positive 
cells beneath the urogenital sinus, which is also Ki-67 positive. As for the remaining 
Müllerian duct epithelium, it is at the time p63 negative, vimentin and PAX-2 positive. By 17 
weeks of gestation, the sheet of p63 positive cells is elongating and forms the utricle, which is 
PAX-2 and vimentin negative. Hence, the utricle is formed by an ingrowth of cells from the 
dorsal wall of the urogenital sinus while the Müllerian ducts regress.  
Melicow published a second article in the early 1970s describing six cases of endometrial 
carcinoma of the prostatic utricle (27). All cases showed histopathological features similar to 
those described in the first article and none of the patients received hormonal therapy nor 
orchiectomy due to the possible adverse effects on a tumor of Müllerian origin. Instead, they 
were treated with transurethral resection of the prostate (TUR-P), RP or radiotherapy. During 
the time that followed, several cases were described, with features such as shaggy-appearing 
tissue close to the verumontanum, elongated glandular structures arranged in a back-to-back 
fashion and areas of papillary architecture complete with true fibrovascular stalks (28). 
Nuclei were described as oval with a nucleolus. Mitotic figures could be seen and the luminal 
aspect of the cytoplasm sometimes showed a frayed appearance with tongues of cytoplasm 
projecting.  
Carney and Kelalis (28) discussed the similar appearance of Melicow and Pachter’s 
endometrioid adenocarcinoma to an already known entity called ductal adenocarcinoma, both 
demonstrating tall, columnar epithelium and a papillary architecture. The most convincing 
feature for the presumed utricular origin was thought to be ciliated tumor cells, which can be 
seen in endometrial adenocarcinoma but never in prostate cancer. However, these were later 
confirmed to be microvilli and not ciliae (29).  
1.7 TWO TUMOR TYPES -ONE DIAGNOSIS? 
Reviewing the literature around the time of the discovery of DAC reveals two similar tumor 
types; one originating from the prostatic utricle, described as endometrial carcinoma, and a 
second group of tumors arising from the prostatic ducts referred to as ductal adenocarcinoma. 
But were they actually members of the same group? Shortly before Melicow and Pachter’s 
discovery, several groups wrote of a tumor type arising from the prostatic ducts, the earliest 
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description by Foot et al. in 1950 (30). The histopathologic features were described as tall, 
columnar epithelium, papillary or cribriform growth, elongated, crowded, hyperchromatic 
nuclei and abundant cytoplasm (31-33). Tumors of the primary prostatic ducts were rarely 
reported at the time (34).  
A study on prostatic adenocarcinomas of ductal origin was published in 1973 describing 55 
cases of ductal type. The cases were divided in two subgroups, adenocarcinomas of the 
primary prostatic ducts and the secondary prostatic ducts (32). Adenocarcinomas of the 
primary ducts were described as composed of papillary fronds with fibrovascular cores, the 
epithelium consisted of a single layer of tall, columnar epithelium with elongated nuclei and 
pale eosinophilic cytoplasm. Adenocarcinomas of the secondary prostatic ducts were 
described as consisting of tall, columnar epithelium, with eosinophilic or clear cytoplasm, 
containing a large, pleomorphic hyperchromatic nucleus. A papillary pattern was observed 
but also areas of cellular outfoldings bridging the cell lumen, creating a papillary-cribriform 
architectural pattern. The lumen was sometimes filled with eosinophilic-like debris, such as 
comedonecrosis, which has later been described in a majority of cases by Christensen et al. 
(17). As many as 95 % of patients had obstructive symptoms.  
Despite the similarities to the endometrial adenocarcinoma of the prostatic utricle described 
by Melicow et al. (16), the authors claimed that the primary duct carcinomas should be 
separated from this entity due to more glandular features in the tumor described by Melicow 
compared to the papillary architecture described by Dube et al. (32). Moreover, the 
endometrial adenocarcinomas did not show osteoblastic metastases nor an elevation in serum 
acid phosphatase as did the primary duct carcinomas. Also, Dube et al. (32) described 
immunohistochemical expression confirming a prostatic origin, with positive acid 
phosphatase reactions and negative aminopeptidase expression.  
Bostwick et al. (35) later suggested that since endometrioid carcinomas and primary or large 
duct adenocarcinomas shared similar clinicopathological features these should be grouped 
together and named prostatic adenocarcinomas with endometrioid features. Due to 
microscopic, ultrastructural and immunohistochemical findings, the term endometrial 
adenocarcinoma was later discarded and the tumors were regarded as adenocarcinomas 
arising from primary prostatic ducts. Due to the similar clinicopathological features of 
endometrioid carcinomas and primary or large duct adenocarcinomas, a distinction between 
the two types did not seem justified but these were grouped together and treated like 
conventional prostate cancers (25).  
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Given this information, it is possible that Melicow and Pachter were actually not the first to 
describe what would later be known as DAC, but merely one of several groups at the time 
describing the same tumor type. Hence, the first description of what would later be known as 
DAC may have been that of Foot et al. (30).  
1.8 CLINICAL FEATURES 
Studies show that patients diagnosed with DAC are slightly older than those with acinar 
adenocarcinoma, the mean age at time of diagnosis ranging from 60-80 years (17, 19, 24, 36, 
37). The urologist may see a patient referred because of macroscopic or microscopic 
hematuria, urinary obstruction, diminished urinary stream or urinary retention (38-41). Less 
common symptoms are anal pain (42) and hemospermia, the latter due to tumor 
fragmentation into the urethra (43). The symptoms described are also seen in patients with 
acinar adenocarcinoma but they are more common in patients with DAC due to the 
sometimes periurethral location (37). Investigation with cystoscopy may show a villous 
lesion protruding from the urethra (24, 33, 42, 44-47). Due to the peripheral as well as 
periurethral location, digital rectal examination may be normal but could also reveal a 
palpable nodularity or induration (17, 19, 35). The patients often present with a clinical stage 
of T2b or higher, classifying the tumors as advanced even at the time of discovery. The s-
PSA range is wide and does not predict findings at RP. Even in metastatic disease, s-PSA 
may be widely scattered and has been reported at 0.3-698 ng/mL with a median of 26 ng/mL, 
not correlating with neither site nor size of the metastasis. Authors have described s-PSA as 
both lower and higher than in patients with acinar adenocarcinomas and the tumor to be less 
likely to be detected by s-PSA screening (17, 48). The conclusion is that s-PSA cannot be 
reliably used to risk stratify patients and that s-PSA does not seem to correlate with findings 
at RP (17). Of interest is that many patients are diagnosed with DAC in RP or TUR-P 
specimens rather than the initial core biopsy of the prostate (49). Lee et al. (50) noted that 
five of six patients with ductal adenocarcinoma had blood group O, but this has not been 
further studied.  
1.9 COEXISTENCE WITH ACINAR ADENOCARCINOMA 
DAC is often seen in combination with an acinar adenocarcinoma and is rare in its pure form. 
Tannenbaum reviewed the pathological files at Columbia-Presbyterian center in 1975 and 
concluded the prevalence of pure DAC to be a mere 0.2 %, the majority being associated with 
an acinar adenocarcinoma (51). Other authors have reported 0.4 % (50) and 0.8 % (35), 
however, it was not specified whether these were pure DAC or mixed tumors. Dube 
separated pure DACs (1.3 %) from mixed (6.3 %) (32). The acinar component is often 
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advanced with a GS of 4 or 5 (35). No difference has been observed between pure DAC and 
mixed cases regarding s-PSA, age, GS, clinical or pathologic stage (49). In summary, DAC is 
most often found together with an acinar component while pure DACs are extremely rare.  
1.10 HISTOPATHOLOGY 
Today, a DAC diagnosis is based on morphology alone. DAC is composed of tall, 
pseudostratified, columnar epithelium with abundant cytoplasm, which is usually 
amphophilic but may be pale or clear (24, 29, 38) Figure 4. Cytoplasmic vacuoles and apical 
snouting are commonly seen (38, 52). The nuclei are basally located and often show a 
prominent nucleolus and a clumped chromatin pattern (38, 53). Mitotic figures (51, 52, 54) 
and luminal necrosis may be seen (35). DAC shows a variety of architectural patterns; 
papillary, cribriform, solid or glandular. Although several patterns are commonly seen in a 
specimen one is usually predominant (32, 52). The papillary architecture is characterized by 
true fibrovascular stalks and the cribriform pattern by back-to-back large glands and 
intraepithelial bridging, forming slit-like lumina (24, 50) Figure 5.  
The location of DAC was initially described as central, often involving the verumontanum 
and the large periurethral prostatic ducts. The peripheral zone (PZ) was not thought to allow 
papillary formations or complex glands due to limited space and stromal formation (35). 
Nevertheless, it has since been shown that DAC involves the PZ preferentially (17, 19, 55). 
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Figure 4 Ductal adenocarcinoma of the prostate (DAC) with typical tall, columnar epithelium and elongated 
nuclei with high-grade features. Hematoxylin and eosin, 20x lens magnification. 
To this day the Gleason grading system remains one of the most powerful predicting factors 
in prostate cancer (56). In the 2006 upgrade of the Gleason grading system, is was concluded 
that a pure DAC should be assigned a GS of 4+4=8 unless comedonecrosis is present, which 
would warrant a GS of 9-10. However, patients with pure DAC have survived for long 
periods despite a high GS (8-10), which suggests that GS may not be useful a prognostic 
factor in this group (49).  
Electron microscopy shows two types of cells arranged in well-defined glandular structures. 
Cells are divided in two types: light and dark. The light cells are composed of secretory 
droplets, lipid filled vacuoles and vesicles, occasional lysosomes and free ribosomes. Dark 
cells have an electron dense cytoplasm with smooth and rough endoplasmic reticuli, 
ribosomes, polyribosomes and numerous mitochondria. In both cell types, a well developed 
Golgi apparatus is found (35, 38, 57). Microvilli are seen on the luminal surface (29). The 
light cells bear resemblance to a well differentiated prostatic adenocarcinoma while the dark 
cells are found in less differentiated parts of the tumor (38).  
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Figure 5 Ductal adenocarcinoma of the prostate (DAC) with tall, columnar, pseudostratified epithelium. Nuclei 
are elongated with high-grade features and the architecture is papillary with true fibrovascular cores. 
Hematoxylin and eosin, 10x lens magnification. 
1.11 IMMUNOHISTOCHEMISTRY 
The immunohistochemical profile of acinar adenocarcinomas is well characterized but for 
DAC it is not. Conventional acinar adenocarcinomas express PSA and PSAP and are 
negative for CK7 and CK20 although expression increases with increasing GS. Alpha-
methylacyl-coenzyme A racemase (AMACR) is over-expressed and basal cell markers such 
as p63 and high molecular weight cytokeratin (HMWCK) are negative (58). Although DAC 
tumors stain positively for PSA and PSAP, which confirms the prostatic origin (24, 44, 47, 
52, 59) the staining may be of variable intensity (57). Two completely PSA and PSAP 
negative DAC tumors have been reported (21, 54), as well as PSA negative metastases (60). 
Nevertheless, it is also known that PSA and PSAP are less expressed in non-DAC tumors of 
GS 8 and above (61).  
DAC may show a focal CK7 and a patchy CK20 staining (62) and a remnant of basal cells as 
demonstrated by HMWCK and p63 staining (58). These are not detected in classical 
adenocarcinomas of the prostate (63).  
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CDX2 and villin are antibodies used to separate prostate cancer from adenocarcinomas of the 
gastrointestinal tract as these are negative in acinar prostate cancer. However, both CEA and 
CDX2 positivity has been demonstrated in DAC (35, 64).  
1.12 GENETIC PROFILE 
During the last decade efforts have been made to reveal the genomic landscapes of not only 
prostate cancers but all common forms of human cancers. A small number of genes are 
altered in most of the tumors while a large number of genes are infrequently altered. A 
decade ago, sequencing one tumor would set researchers back more than 100 000 USD, 
however, the prices have dropped and sequencing is now the norm, thus facilitating the 
understanding of tumor biology and the development towards personalized cancer medicine.  
Most tumors show different genetic signatures. This is also seen in the daily clinical work of 
urologists and oncologists: not two patients follow an identical clinical course. Possible 
explanations are non-genetic and host factors, including vascular permeability to drugs or 
germline variants deciding the drug half time (65). Another explanation is somatic mutations 
in the tumors. A DAC tumor may have several different mutations but if you compare tumors 
from two different patients they may only share a few mutations, often located in driver genes 
(66). Nevertheless, even if the mutations occur in the same driver genes, the mutations 
themselves may differ. As different domains of the protein will be altered, the cellular 
properties may differ (67).  
Frequently mutated genes in prostate cancer include PTEN, TP53, FOXA1 and SPOP (68, 
69) while the TMPRSS2-ERG fusion is the most common fusion gene in prostate cancers, 
occurring in 40-60 % of all cases (70). The gene fusion occurs through a deletion on 
chromosome 21 or through a translocation, the deletion being more common. TMPRSS2 is 
an androgen regulated gene while ERG is a member of the ETS transcription family. The 
fusion results in ERG being brought under the control of an androgen regulated promotor, 
hence there is an over expression of protein (70). In reports, the fusion has not been found to 
correlate with prognosis (71). Other genetic alterations include AR amplification and loss of 
NKX3.1. Together or separately, these alterations account for the development of prostate 
cancer and for some patients the development to metastatic, castration resistant disease (72, 
73).  
Although DAC has been known for 50 years and recent advances have been made in the 
technique of genome sequencing, few studies have investigated the genetic profile of DAC. 
One study showed a high degree of molecular relatedness to acinar adenocarcinomas but a 
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lower frequency of the TMPRSS2ERG gene fusion (74). Although the TMPRSS2ERG 
fusion does occur in DAC, it is less commonly seen than in pure acinar adenocarcinomas. 
The fusion gene was found in 45 % of acinar adenocarcinomas but only in 11 % of DAC and 
5 % of the acinar components of mixed tumors (74, 75). As the expression was low also in 
the acinar component, this suggests that different genetic events may lead to a mixed ductal-
acinar cancer than to a pure acinar adenocarcinoma. It has been hypothesized that as DAC 
sometimes presents with a low s-PSA, the level of circulating androgens may be lower, which 
could lead to less frequent rearrangements (75).  
AR is a ligand-dependent nuclear transcription factor and the main therapeutic target in 
prostate cancer. The AR signaling pathway is disrupted in many prostate cancers, often 
through AR itself but also through its pathway members such as FOXA1, SPOP or NCOR1/2 
(76). Together with ETS fusions, SPOP is one of the driver events in tumorigenesis (68). 
PIK3C may be altered in metastatic, castration resistant prostate cancer through 
amplifications, fusion and/or hot spot mutations (76). FOXA1, when mutated, represses 
androgen signaling and promotes tumor growth through promotion of cell cycle progression 
(77, 78). It is unknown whether any of these genetic changes occur in DAC.  
Sanati et al. (79) showed that DAC and acinar adenocarcinomas are highly molecularly 
related. Among the differentially expressed gene transcripts were CD24 and cadherin-like 23, 
involved in cell adhesion and the prolactin receptor, which was over expressed. Prolactin has 
been shown to promote ductal morphogenesis and increase the ductal epithelium in rodent 
prostates (80, 81).  
Subsequent genetic events occurring after cancer initiation includes PTEN homozygous 
deletions. In a recent study, 37 DAC and 18 matched acinar adenocarcinomas were examined 
by immunohistochemistry with genetic validation (75). PTEN loss was often seen in acinar 
adenocarcinomas but was infrequent in both pure and mixed DAC. Also, PTEN loss was not 
enriched in ERG positive tumors, a common observation in acinar adenocarcinoma (75). As 
PTEN and ERG status are similar in DAC and the acinar component it is possible that the 
two types are clonally related.  
DAC may grow in an environment low of sex hormones, shown as a decreased expression of 
SQLE, 5AR2 and aromatase. SQLE is the rate limiting enzyme of cholesterol synthesis 
expressed in prostate cancer cells, especially in high grade prostate cancer (82). An up-
regulation of BCAR1 and Src is also seen, both molecules are associated with aggressive 
prostate cancer. Src belongs to the family of Src kinases that is responsible for signal 
  - 16 - 
transduction from certain receptors on the cell surface. The downstream cytoplasmic effector 
is BCAR1/p130 CAS, which is involved in proliferation, migration and survival (83). These 
have also been shown to be over-expressed in castration resistant prostate cancer.   
Metastatic castration resistant prostate cancer shows copy number alterations and 
amplifications in PIK3CA, PIK3CB and CCDN1 as well as deletion peaks in CHD1, PTEN, 
RB1 and TP53, the latter being the most commonly mutated gene in all human cancers (84). 
CHD1 negative tumors may be ETS negative and show mutations in SPOP and this may be 
viewed as a separate class of prostate cancer (77). Patients with DAC may present with 
metastases but it is unknown which genetic modifications they may harbor. 
In summary, the few studies made on the genetic profile of DAC show that the ETS fusion is 
less common, PTEN loss is less frequently seen in both DAC and the associated acinar 
component in mixed cases and PTEN loss is not enriched in ERG positive tumors, which is 
seen in acinar adenocarcinomas (75).  
1.13 PROGNOSIS 
The prognosis of DAC is generally considered poor with patients presenting at an advanced 
clinicopathological stage, with or without metastases (17, 19). To this day, it is not known 
whether the poor prognosis is the result of the high grade features or the sometimes central 
location allowing occult growth and metastasizing (59). Moreover, it is not fully known how 
the size of the DAC component influences outcome in a mixed ductal-acinar tumor. Amin et 
al. (85) found that the pathologic stage of GS 7 cancers with less than 10 % DAC did not 
differ from that of acinar adenocarcinomas of GS 7. Moreover, the combination of DAC and 
acinar cancer makes it difficult to tell whether the acinar or the ductal component accounts 
for disease progression.  
DAC was initially thought to have a favorable prognosis as no patients died from their 
disease in early follow-ups ranging from 0-60 months (16, 28, 39, 45, 86, 87). The hypothesis 
was that the intraurethral location led to an early discovery when patients sought health care 
because of hematuria, obstructive or irritative symptoms. Hence, the tumors were found at a 
low grade (16, 28, 39, 45, 86, 87). Some authors even thought of DAC as a tumor with no 
metastatic potential (51). Mixed ductal-acinar cases were thought to have a worse prognosis, 
the acinar component being viewed as the outcome-determining factor (31, 50, 52). 
More recent studies have confirmed DAC to be a subtype with poor prognosis. A study by 
Bostwick et al. demonstrated the 5-year survival to be a mere 15 % with more than 50 % of 
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patients dying of metastatic disease within 9-70 months after diagnosis (35). Oxley et al. 
showed that DAC patients with a high proliferative index as demonstrated by Ki-67 were 
dead of disease one, three and four years, respectively (88). Ki-67 labeling index is known to 
be an independent prognostic factor in prostate cancers treated by RP (89). DAC has a high 
short-time failure rate after RP compared to acinar adenocarcinomas (17). Patients with DAC 
may progress without biochemical recurrence, illustrating that DAC may not produce PSA to 
the same extent as acinar cancers (90). This suggests that even a patient showing a complete 
response in s-PSA after treatment may progress in his disease.  
Christensen et al. (17) examined DAC tumors in RP specimens and compared them against 
acinar adenocarcinomas of similar stage. DAC cases had a large tumor volume and the 
pathologic stage was advanced, 93 % of patients had EPE, 47 % positive surgical margins, 40 
% SVI and 27 % had tumor infiltration of pelvic lymph nodes. The DAC component in 
mixed ductal-acinar cases often contributed to the EPE. EPE and SVI are more frequently 
observed as tumor volume increases together with perineural invasion. The progression rate 
of DAC has been compared to that of GS 7-9 acinar tumors (19). Pure DAC tends to pursue 
an indolent course but has an increased risk of local recurrence (49). This suggests that local 
treatment and control may improve the clinical course for patients with pure DAC.  
1.14 METASTATIC SITES 
Metastases are three times more common at time of diagnosis in patients with DAC than in 
patients with acinar adenocarcinoma (18). The metastatic sites were initially thought to be 
similar to those of acinar adenocarcinoma, namely bone and lymph nodes. However, DAC 
has later been shown to have a propensity to spread to visceral organs such as lungs and brain 
(35, 49, 91) but also to the penis and testes, which are unusual metastatic sites for acinar 
adenocarcinoma (92, 93). Metastases to the penis from any site are rare and until recent date 
only about 400 cases have been reported in the literature, the first one already in 1870 (94). It 
may be difficult to recognize a DAC metastatic to the penis because of the unusual anatomic 
site for prostate cancer, varying morphology, no history of prior prostate cancer or a long 
interval from the primary prostatic lesion (93). DAC has also been found to metastasize to the 
anterior urethra, liver and skin, prostate cancer metastatic to the skin being very rare with an 
incidence of 0.36 % (60, 90, 95, 96). Metastases may be pure DAC, acinar or mixed (24, 57, 
60).  
It is crucial to diagnose the site of origin of a metastatic adenocarcinoma as cancer therapies 
are increasingly organ specific. DAC is over-represented at unusual metastatic sites and may 
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resemble other adenocarcinomas histologically, meaning that the tissue origin may be 
difficult to establish. Immunohistochemical stains may be useful for the identification of 
tumor origin. Looking at morphological features, it is not difficult to understand why the first 
authors thought that DAC was related to endometrial adenocarcinoma Figure 7. 
Gastrointestinal tumors such as rectal and colon adenocarcinomas may show overlapping 
features with tall, columnar epithelium and complex glands (97). However, staining for 
intestinal markers such as CDX2 and CEA in combination with prostate specific markers 
PSA, PSAP or prostein can be used to confirm the intestinal origin. Copeland and al. (91) 
have described the possibility of misdiagnosing DAC metastases in the lung as a primary 
pulmonary or colorectal adenocarcinoma, demonstrating the need for immunohistochemical 
panels.  
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Figure 7 A) Ductal adenocarcinoma of the prostate (DAC) with papillary architecture and fibrovascular stalks. 
Tall, columnar epithelium with high-grade nuclei and prominent nucleoli. Hematoxylin and eosin (H&E), 20x 
lens magnification. B) Colon adenocarcinoma with columnar epithelium, elongated high-grade nuclei and 
prominent nucleoli. H&E 20x. C) Lung adenocarcinoma with papillary architecture. Cells are columnar with 
elongated high-grade nuclei and prominent nucleoli. H&E, 20x. D) Endometrial adenocarcinoma with papillary 
architecture and fibrovascular stalks. Cells are columnar with prominent nucleoli. H&E, 20x. E) DAC stained 
with Ki-67. H&E, 40x. F) Colon adenocarcinoma stained with Ki-67, demonstrating a higher labeling index than 
seen in DAC (E). H&E, 40x. Seipel et al. 2015 
  - 20 - 
1.15 TREATMENT 
Because of the supposed female tissue origin, Melicow and Pachter believed that treatment 
with orchiectomy or estrogen was contraindicated (16). They were supported by a clinician 
who wrote a letter to the editor of Archives of Pathology & Laboratory Medicine in 1973, 
stating that castration and other forms of hormonal therapy were probably worthless as 
treatment for DAC (98).  
Nevertheless, the tumors were later found to respond well to hormonal treatment as well as 
orchiectomy (24, 29, 99). As further studies proved a prostatic origin of these tumors DAC 
was treated in the same manner as conventional adenocarcinomas. Modern treatment 
modalities for DAC include RP, TUR-P, radiation therapy in form of external beams or 
brachytherapy, hormonal therapy or a combination of the above (100). Patients with DAC are 
more likely to undergo RP than patients with an acinar adenocarcinoma of GS 8-10 (101). 
The response to hormonal therapy was initially described as poor (32, 102) but is now 
considered similar for DAC and acinar adenocarcinomas, with similar relapse and regression 
rates (103). Orihuela and Green suggested that a combination of radiation and hormonal 
therapy might be the best treatment option for patients with localized DAC (90). 
Radiotherapy has been shown to be of benefit for local control of local recurrence but not as 
curative treatment (104). Staging with whole body scan and computer tomography (CT) of 
chest, abdomen and pelvis should be performed in all patients, possibly even of the brain due 
to the distribution of metastases of this tumor subtype. Due to the aggressive nature of DAC 
tumors, it is possible that adjuvant treatment should be added (105), nevertheless conflicting 
results have been shown (35).  
The large proportion of EPE, positive surgical margins, SVI and pelvic lymph node 
metastases in patients who were initially thought to have resectable disease suggests a clinical 
underestimation of the extent of DAC tumors (17, 19). RP may even be a poor choice of 
treatment strategy for these patients. A high risk of local recurrence has also been 
demonstrated after RP (106). However, it should be noted that some studies were conducted 
before the PSA era, thus it is not possible to determine whether poor results post-RP are due 
to a delayed diagnosis or a poor choice of treatment.  
In summary, studies show variable efficacy of RP, hormonal treatment, radiotherapy and 
chemotherapy, which is likely the result of small studies, a timeline of 50 years and variable 
inclusion criteria. A prostate cancer with a DAC component of any size should be treated as 
high-risk disease due to its potential to spread locally and the likelihood of metastasizing 
(36).  
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1.16 DAC -A TRUE SUBTYPE? 
Since the discovery of DAC it has been debated whether it should be considered a separate 
clinical entity (107). About 40 years ago, Rotterdam and Melicow described a mixed ductal-
acinar case, stating that the two components should be considered as neoplasms with different 
cell origin, biologic potential and histopathologic features (46).  
In 1999, Bock and Bostwick questioned the existence of DAC, challenging its status as a 
unique subtype due to the considerable overlap with acinar adenocarcinoma, particularly in 
small tissue specimens. Reviewing a series of 338 consecutive RP specimens, the authors 
identified cases with clinicopathological findings of acinar adenocarcinomas. The series 
included typical PZ cancers that apparently did not involve the large periurethral prostatic 
ducts or verumontanum. Among the 338 cases the authors searched for ductal features in 
terms of papillary or cribriform architecture, which were at least 5 mm in diameter. In 5 % of 
the cases, ductal features were identified. They concluded that adenocarcinomas arising in the 
PZ of the prostate may display papillary or cribriform growth, features associated with DAC. 
Together with the almost constant association of DAC and acinar adenocarcinoma this led 
them to the conclusion that DAC is the result of the spread of typical acinar cancer to the 
large periurethral ducts and stroma. The only unique histologic feature of DAC would be the 
site of growth (107).  
Supporting the view of DAC as a distinct subtype are current immunohistochemical findings, 
clinical behavior, genetic profile and morphology. The morphology with tall, columnar, 
pseudostratified epithelium arranged in papillary, cribriform and/or glandular structures is 
different from a typical acinar adenocarcinoma and the clinical outcome with a large extent of 
EPE, SVI, positive surgical margins and rate of metastasis suggest that it should, in fact, be 
viewed as a separate entity and treated accordingly. Despite evidence suggesting that DAC is 
a separate subtype, no immunohistochemical markers or diagnostic features can with 
certainty be used to diagnose DAC.  
1.17 DIFFERENTIAL DIAGNOSES 
Several benign and malignant lesions may be confused with DAC. Lesions protruding into 
the urethra, such as papillary transitional cell carcinoma of the prostatic urethra and inverted 
urothelial papilloma may mimic the appearance of DAC (28). A benign fibroepithelial or 
prostatic polyp in a young male may cause macroscopic hematuria, a symptom sometimes 
seen in DAC (108). Other lesions occurring in the urethra are proliferative papillary urethritis, 
caruncle, urothelial papilloma, polypoid adenocarcinomas and nephrogenic adenomas. As 
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DAC may arise from villous polyps, a centrally located DAC can mimic benign urethral 
polyps, clinically and histopathologically (62, 86).  
High grade prostatic intraepithelial neoplasia (HGPIN) consists of glands lined by atypical 
cells and may mimic DAC in a RP or core biopsy specimen. The architectural pattern is 
tufting, micropapillary, cribriform or flat. The micropapillary pattern is characterized by 
papillary projections into a glandular lumen (109). As opposed to DAC, HGPIN does not 
contain true fibrovascular stalks, the glands show the same size and distribution as benign 
glands and not the large, back-to-back oriented glands found in DAC. Features seen in DAC 
but not in HGPIN also include perineural invasion, hemosiderin deposition and stromal 
fibrosis (19). Separating DAC from HGPIN on core needle biopsies may be difficult due to 
the limited tissue available. As an adjunct to histopathological characteristics, Ki-67 staining 
can be used, the expression being higher in DAC (110).  
Pseudohyperplastic adenocarcinoma has a columnar appearance, papillary infoldings and 
abundant cytoplasm, features similar to those of DAC (111). The nuclear atypia is generally 
less pronounced than in DAC. Distinction is important as pseudohyperplastic 
adenocarcinoma is considered a Gleason pattern 3 while DAC usually is assigned a Gleason 
pattern 4. The PIN-like ductal adenocarcinoma of the prostate may be seen as long strips of 
PIN-like epithelium lining the edge of a biopsy specimen, however, the marked 
pleomorphism, cribriform, papillary or solid architecture seen in DAC is missing (112). 
Intraductal carcinoma (IDC) is also known for its resemblance to DAC, however, the cells 
form dense cribriform patterns with rounded lumina or micropapillary tufts without 
fibrovascular stalks (85). The nuclei are more rounded and the epithelium is not as columnar 
but the distinction is not always obvious (85). IDC represents intraductal growth of acinar 
adenocarcinoma and may co-exist with DAC in as many as 16 % of RP specimens. More 
than 30 % of DAC has been show to grow intraductal, which further complicates the 
distinction (58) Figure 8.  
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Figure 8 Intraductal prostate cancer, a common differential diagnosis to ductal adenocarcinoma of the prostate 
(DAC). The typical tall, columnar epithelium and elongated nuclei seen in DAC are missing. Hematoxylin and 
eosin, 10x lens magnification. 
DAC may also be found together with other rare histological patterns such as mucinous, 
goblet cell, foamy gland, Paneth cell, neuroendocrine, micropapillary or cystic features 
although these account for only ten known cases in the literature to date (113).  
1.18 FUTURE CHALLENGES 
Although half a century has passed since the first descriptions of DAC, the clinical and 
prognostic implications of DAC remain somewhat controversial. The major limitation in 
studies is that the tumor is rare. A majority of studies include only a handful of cases as large 
series are difficult to collect at single institutions. Recent studies including a large number of 
cases have used database searches, which is an unreliable method as the diagnosis of DAC is 
known to be challenging even for experienced uropathologists (18, 101). Hence, DAC cases 
may have been overlooked or differential diagnoses included. The collection of DAC cases 
should therefore be done by central review by an experienced pathologist. Multicenter studies 
with central review are needed for verification of results from smaller single-center studies.  
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The lack of diagnostic criteria for DAC may explain some of the differences observed 
between studies. There is a need for standardized diagnostic criteria as well as further studies 
on the genetic as well as the immunohistochemical profile of DAC. As we move towards 
personalized cancer medicine, acquiring knowledge about aggressive subtypes such as DAC 
may be the key to optimize treatment and clinical outcome.  
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2 AIMS 
The aim of this thesis was to investigate and better characterize the prostate cancer subtype 
ductal adenocarcinoma (DAC), which continues to challenge pathologists half a century after 
its first discovery. Briefly, our aims were to examine; 
 
 
• Which cancers should be classified as DAC and which criteria should be used 
for diagnosis? 
 
• Do any of the histopathologic characteristics of DAC show a correlation with 
poor prognosis? 
 
• Does DAC have a different immunohistochemical profile than acinar 
adenocarcinomas? 
 
• How do we distinguish DAC from adenocarcinomas of other origin if sampled 
at a metastatic deposit? 
 
• Are there genetic differences between DAC and acinar adenocarcinomas? 
 
• Is DAC a separate entity or merely a variant of acinar adenocarcinoma? 
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3 MATERIAL AND METHODS 
“It always seems impossible until it’s done”  
     —Nelson Mandela 
3.1 TISSUE COLLECTION AND PREPARATION 
Cases for Study I-IV (114-117) were identified after the review of a consecutive series of 
1’156 specimens from patients who underwent RP at Karolinska University Hospital between 
May 1998 and December 2005. Patients were excluded if they had received neoadjuvant 
treatment (hormonal treatment or radiotherapy), gone through TUR-P or if there was no 
clinical follow-up available. A total of 1 051 cases remained for study. For Study III and IV 
additional cases were acquisitioned from Aquesta Pathology, Queensland, Australia and for 
Study V (118) by searching records at Karolinska University Hospital for DAC cases with 
fresh-frozen tissue available.  
The RP specimens were formalin-fixed overnight in 4 % buffered circulating formal saline, 
inked and totally embedded, sections were then cut horizontally at 4 mm thickness. Slices 
were either mounted or cut into 2-6 segments. The apex and base were handled using the 
shave technique 1998-2003 and from 2004 by coning with sagittal slicing of the apex and 
shaving of the base. The RP specimens were then dehydrated, paraffin embedded and cut at 4 
µm. The sections were stained with hematoxylin and eosin (H&E) for histopathologic 
evaluation.  
Fresh-frozen tissue for Study V was collected from RP specimens by cutting a horizontal 
slice with a double-bladed knife. The slice was cut into smaller blocks and put in cryomolds 
filled with OCT gel, snap frozen in liquid nitrogen and stored at -80°.  
3.1.1 Study I 
All slides from the series of 1 051 RP specimens were reviewed by the author for any 
presence of DAC, which was later confirmed together with a senior pathologist (Lars Egevad, 
LE). Ductal cancers were classified into three subgroups according to histopathological 
features. 
DACC 
A case was classified a ductal adenocarcinoma of classical type (DACC) if the tumor 
occupied more than one visual field, had tall, columnar, pseudostratified epithelium, 
prominent nucleoli, elongated or oval nuclei, papillary/cribriform/glandular architecture or a 
mixture of several types. The nuclei were crowded and had high-grade features with open 
chromatin and rough chromatin texture. The cytoplasm was amphophilic or clear. Table 1. 
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DACB 
A ductal adenocarcinoma with borderline features (DACB) showed several of the 
characteristics described for DACC but would lack elongated nuclear shape or typical 
architectural features. A case was also classified as DACB if the extension was less than 
focal, or less than one medium power field. Two different types were often seen, one where 
the nuclei would be located basally but show stratification and a complex glandular 
architecture with papillary infoldings. A second type showed elongated, stratified nuclei as 
seen in DACC, but the architecture was simple and glandular Table 1, Figure 9. 
 
Figure 9 Ductal adenocarcinoma with borderline features. The tall, columnar epithelium can be seen, however, 
the typical nuclear features are missing. 
PCDF 
A prostate cancer with ductal features (PCDF) had stratified, high-grade nuclei but lacked the 
other characteristics of DACC. The nuclei were not elongated but had other high-grade 
features Table 1, Figure 10. 
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Figure 10 Prostate cancer with ductal features. The nuclei are stratified and of high-grade but the typical 
architecture and the columnar, pseudostratified epithelium seen in ductal adenocarcinoma of the prostate is 
missing. Hematoxylin and eosin, 20x lens magnification.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Describing the histopathological features of the three subgroups of ductal adenocarcinoma of the 
prostate 
 DACC DACB PCDF 
Feature    
Columnar, pseudostratified epithelium Yes Yes No 
Elongated nuclei Yes Y/N No 
Stratified, high grade nuclei Yes Yes Yes 
Architecture, one or more:    
Cribriform Yes Y/N No 
Papillary Yes Y/N No 
Glandular Yes Y/N No 
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Cases identified 
A total of 86 cases were identified of which 27 were classified as DACC, 42 as DACB and 
17 as PCDF. 
3.1.2 Study II 
For Study II, 21 cases from the DACC and DACB group of Study I were included; 14 DACC 
and 7 DACB. Cases with a range of histopathological features were selected.  
3.1.3 Study III and IV 
A total number of 35 DAC cases from the DACC and DACB group of Study I were chosen 
based on sufficient tumor tissue volume. Acinar adenocarcinomas matched for GS were 
chosen as controls and a total number of 46 cases were included.  
Cases from Aquesta Pathology, Brisbane, Australia were added to increase the total number 
of DAC cases. For Study III, records were searched for RP or TUR-P specimens containing 
DAC tissue and a total of 25 cases were identified; 23 RP and 2 TUR-P specimens. Blocks 
were sent to Karolinska University Hospital and all cases were included in the tissue 
microarray constructed for Study III and IV.  
For Study IV, records were searched at Karolinska University Hospital for adenocarcinomas 
with morphological features similar to those of DAC. A total number of six colonic 
adenocarcinomas, seven endometrial adenocarcinomas, five gastric adenocarcinomas, seven 
lung adenocarcinomas, five pancreatic adenocarcinomas and seven urinary bladder 
adenocarcinomas were included.  
3.1.4 Study V 
Records were searched at Karolinska University Hospital for prostate cancers with a DAC 
component and available fresh frozen-tissue. Formalin-fixed paraffin embedded sections 
were reviewed for presence of DAC and the corresponding fresh-frozen tissue was then 
cryosectioned, stained and reviewed for any presence of DAC. Benign tissue from all cases 
was used as control. Eleven cases were included in the study.  
3.2 PHOTOMICROGRAPHS 
For Study II photomicrographs were taken and distributed together with a questionnaire, 
using a web based survey tool (www.surveymonkey.net). A set of six photomicrographs were 
taken, three at 10x and three at 20x lens magnification. Pictures of several areas were taken 
and critically examined in order to ensure an accurate, objective and valid description of each 
case (119). Photographs were reviewed together with a senior pathologist (LE) before the 
final series was chosen.  
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3.3 TISSUE MICROARRAYS 
For Study III and IV a tissue microarray (TMA) was constructed consisting of two paraffin 
blocks. One core of tumor tissue of 1 mm size was harvested from each case, resulting in two 
slides with 145 cases in total Figure 11.  
 
Figure 11 One section from each final paraffin block stained with hematoxylin and eosin. Cores are arranged in 
asymmetrical patterns to allow easy identification of each separate case. 
A TMA is a method, which is used to collect a large number of cases in a single paraffin 
block. The method was described by Battifora in 1986 as a method for immunohistological 
testing of a large number of samples on a single slide with only one drop of antibody (120). 
The method was modified in 1990 when the tissue was distributed in a checkerboard pattern 
(121). Kononen et al. (122) subsequently refined the method and enabled in-situ detection of 
DNA, RNA and protein targets, allowing up to 1 000 cores in one 45 x 20 mm block.  
The first step in the construction of a TMA is to use an H&E section from the donor block to 
identify areas of interest and verify that enough tissue is still available in the block. One or 
more tissue cores are punched out from the donor block and transferred to pre-made holes in 
the recipient block. Cores are arranged in precise but asymmetrical patterns to allow 
identification of separate cases while maintaining orientation. Sections are then cut from the 
recipient block using a microtome and these sections are later stained and analyzed. TMAs 
are used for histochemical, immunohistochemical and immunofluorescent staining as well as 
DNA and RNA hybridization. Depending on the core length, one block may theoretically 
provide 100 to 200 sections (123), although the number of sections that can be harvested is 
usually lower in practice.  
3.3.1 Number of cores 
In our studies we used one 1 mm core of tumor tissue from each case. It has been debated 
how many cores should be sampled from each tumor and what the core size should be. 
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Kononen et al. (122) stated that as many tumors are heterogeneous, a single sample is 
insufficient for representation of the biological properties. Instead, several samples should be 
taken from the most representative areas of each tumor. Core size may vary, common sizes 
are 0.6, 1.0, 1.5 and 2.0 mm. Large cores of 2.0 mm size may damage the donor as well as the 
recipient block. Rubin et al. (124) concluded that no less than three 0.6 mm cores should be 
taken to assess tumor protein expression while more than 4 cores of 0.6 mm did not add 
significant information. However, Tennstedt (125) showed that using multiple 0.6 mm cores 
does not necessarily increase the ability to associate biomarkers with prognosis or tumor 
phenotype but may introduce statistical errors because of unequal amounts analyzed per 
tumor. The authors also debated the use of only one section of an RP specimen as the golden 
standard to find relevant biomarkers for prostate cancer. The mean volume of prostate cancer 
in 1 657 RP specimens was 4.4 cm3, meaning that one 4 µm section containing 2x1 cm of 
tumor would only analyze 0.00008 cm3 of the tumor, hence 0.0018 % ! Including two more 
cores does not add a substantial amount of information. Also, the addition of multiple 
positively stained cores may not reflect tumor heterogeneity but rather false positive or non-
specific staining (125). The use of several cores is expensive, time consuming and depletes 
the paraffin blocks of tumor tissue. Hence, the use of 1 mm cores in our studies is supported 
by the literature and as DAC tissue is sparse, the choice was also made not to exhaust the 
blocks by using more than one core.  
3.4 IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) is used to analyze protein expression in tissue and the method 
was used in Study III and IV. A summary of antibodies used is seen in Table 2. Antibodies to 
estrogen, progesterone and androgen receptor, prolactin, PSA, prostein, PSMA, PSAP, 
CDX2, lysozyme, villin, monoclonal CEA, CK7, CK20, HMWCK, p63, p504s, c-myc, 
epithelial growth factor receptor (EGFR), Ki-67, p16, p21, p27, p53, PTEN, ERG, PAX-2 
and PAX-8 were used. Sections were stained at the routine lab of the Department of 
Pathology, Karolinska University Hospital using a Leica Bond robotic immunostainer (Leica 
Microsystems, Wetzlar, Germany), or a Ventana automated immunohistochemistry system 
(Ventana Medical Systems, Tucson, AZ, USA).  
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Antibody/clone Species/Type Dilution Antigen retrieval Vendor 
Androgen 
receptor 
Rabbit/monoclonal Prediluted CC1 64 min Ventana 760-4605 
CDX2 Rabbit/monoclonal 1:50 H2 Cell-Marque 23R-
16 
CEA 
monoclonal 
Mouse/monoclonal 1:400 H1 Dako M7072 
CK7 Mouse/monoclonal Prediluted H2 Novocastra 
PA0942 
CK20 Mouse/monoclonal 1:100 E1 (10) Dako MR019 
C-myc Mouse/monoclonal 1:24 CCI 64 min Amp+u-w Neomarker M5139 
EGFR Mouse/monoclonal 1:600 E1 (5) Dako M7239 
ER 
HMWCK 
Rabbit/monoclonal 
Mouse/monoclonal 
Prediluted 
Prediluted 
CC1 64 min Amp+u-b 
Protease 1 8 min 
Ventana 790-4324 
Ventana 790-4373 
Ki-67 Rabbit/monoclonal Prediluted CC1 36 min + u-b Ventana 790-4286 
Lysozyme Rabbit/polyclonal 1:2500 E1 (5)  Dako A099 
p16 Mouse/monoclonal 1:400 H1 Santa Cruz sc5660 
p21/WAF-1 Mouse/monoclonal 1:50 H1 Calbiochem OP64 
p27 Mouse/monoclonal 1:40 H1 Novocastra NCL-
P27 
p504S/AMACR Rabbit/monoclonal 1:100 CC1 36 min + Amp Dako M3616 
p53 Mouse/monoclonal Prediluted CC1 64 min +Amp u-b Ventana 800-2912 
p63 Mouse/monoclonal Prediluted CC1 52 min + Amp u-w Ventana 760-4509 
PAX-2 Rabbit/polyclonal 1:100 H2 Abcam ab23799 
PAX-8 Mouse/polyclonal 1:200 H2 Proteintech Europa 
10336-1-AP 
PgR Rabbit/monoclonal Prediluted CC1 64 min + u-b Ventana 790-2223 
Prostein/P501S Mouse/monoclonal 1:100 H1 Dako M3615 
PSA Mouse/monoclonal 1:100 H2 Novocastra NCL-
PSA-431 
PSMA Mouse/monoclonal 1:50 H1 Dako M3620 
PSAP Mouse/monoclonal 1:200 H1 Novocastra NCL-
L-PAP 
PTEN Mouse/monoclonal 1:400 H2 Novocastra NCL-
PTEN 
Villin Mouse/monoclonal Prediluted H1 Novocastra 
PA0106 
ERG Rabbit/monoclonal Prediluted CC1 36 min Ventana 790-4324 
Prolactin Rabbit/polyclonal Prediluted  CC1 36 min + u-w Ventana 760-2803 
 
 Table 2. Antibodies used in Study III and IV. CCI= citrate buffer pH 6.0, heated 36/52/64 minutes, u-b= ultra 
block, u-w= ultra wash, E1= 1 drop of conc. enzyme+ 7 ml Bond enzyme solution, Protease 1= Proteolytic 
enzyme, Amp= amplification of DAB antigen, H1= pretreatment with Bond Epitope Retrieval Solution 1, H2= 
pretreatment with Bond Epitope Retrieval Solution 2. Seipel et al. 2014 
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The principles of IHC date back to the 1930s but it was not until 1942 that Coons et al. (126) 
used labeled antibodies to identify Pneumococcal antigens in infected tissue. Tissue samples 
must be rapidly preserved to prevent breakdown of cellular proteins and architecture. 
Formaldehyde is commonly used for fixation, creating a semi-reversible covalent 
crosslinking. The tissues are then embedded in paraffin to preserve the natural shape and 
architecture for histopathologic examination. Sections are cut and mounted on glass slides.  
In order for the antibodies to recognize and reach the target antigens, samples must be de-
paraffinized. Removal of the paraffin is done by washes with xylene followed by graded 
washes with ethanol to remove the xylene and washes with ethanol and water to rehydrate the 
specimen. The formaldehyde creates methylene bridges between proteins, thus masking 
epitope recognition by primary antibodies. These bridges are removed either using heat-
induced epitope retrieval or proteolytic-induced epitope retrieval.  
Endogenous target activity must then be blocked to avoid recognition of endogenous biotin 
with the targeted antigen. Biotin is a co-enzyme in many reactions and is conjugated to 
antibodies and enzymes because it has a strong binding affinity with avidin and thus 
facilitates visual recognition of the complex. Our cells, however, may contain high levels of 
biotin, which causes the avidin to bind, thus creating background staining. To prevent this, 
free avidin is administrated to the sample and biotin is then added, making the biotin fill all 
available biotin-binding sites on the avidin molecule.  
Antibodies have an affinity for specific epitopes but may nevertheless bind to non-specific 
sites similar to their binding site on a specific epitope. This also causes background staining. 
To reduce this, samples are incubated with a buffer that blocks the reactive sites.  
Primary and secondary antibodies are diluted to promote homogeneous distribution, stabilize 
the antibody and to reduce non-specific binding. The sample is rinsed between the application 
of the primary and secondary antibody to wash off any excess antibody that may have bound 
to a non-specific site. Antigen detection methods are indirect or direct Figure 12. In the direct 
method, a primary antibody conjugated to an enzyme recognizes its epitope and binds. The 
enzyme is activated by adding a substrate, which allows visual detection of the complex. The 
indirect method uses a secondary antibody specific for the primary unlabeled antibody, which 
is added first. As multiple secondary antibodies may bind to the primary antibodies this 
allows for amplification of the signal, thus facilitating visual recognition of the detectable 
product.  
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Figure 12 Describing the two principles of antigen detection, direct (left) and indirect (right). 
3.4.1 Evaluation 
Immunohistochemical staining in Study III and IV was evaluated by the author. Cases with 
interpretation difficulties were re-assessed in open discussion together with a senior author 
(LE).  
3.5 LASER CAPTURE MICRODISSECTION 
All tissues in the human body are composed of different cell types. Cells in complex tissues 
are affected by their surroundings and the microenvironment. The analysis of gene expression 
patterns requires pure cell populations without contamination of other cell types. If the DNA 
or RNA acquired are not from a homogeneous population but from several cell types, no 
conclusions about the specific disease morphology can be made. Laser capture 
microdissection (LCM) allows the isolation of a pure group of targeted cells in a microscopic 
region for further analysis and has been modified since its introduction in the early 21th 
century.  
Different methods have been used to isolate pure cell populations; one method was to destroy 
the unwanted regions using an ultraviolet laser beam and then collect the remaining wanted 
cells mechanically. This was described already in 1976 by Meier-Ruge et al. (127) and used 
by several authors at the time (128, 129). Another option was to remove the desired region 
manually using a tool such as a needle or a blade (128, 130).  
The modern day LCM was invented at the National Cancer Institute of the National Institutes 
of Health in Bethesda, USA (131). The authors described a method in which a thin, 
transparent film was placed over a tissue section. The cells of interest were adhered to the 
film using a pulse from an infrared laser. The film together with the area of cells of interest 
could then be transferred directly into, for example, a buffer for downstream analysis. The 
advantages were time, preservation of original morphology, avoiding manual manipulation 
and contamination of the material and above all, it was a simple method fulfilling the needs 
of clinicians and researchers in daily work (131). The method is an example of an infrared 
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laser capture microdissection system and the method was quickly commercialized by 
Arcturus Engineering.  
Another platform is the ultraviolet laser microbeam microdissection system, which was 
described by Schütze and Lahr in 1998 (132). The sectioned tissue is mounted on a 
membrane slide and a laser beam is used to cut the region of interest on the slide under direct 
visualization, creating a gap between the region of interest and the surrounding cells. The 
power of the laser is then increased and the cut region is catapulted up into a collecting tube. 
This method was commercialized by PALM Zeiss Microlaser Technologies and used in our 
studies.  
The greatest advantages of LCM are the speed and the precision, allowing even the dissection 
of single-cells without destroying the adjacent tissue. A range of tissue can be used, from 
formalin-fixed paraffin embedded material to live cells and cell cultures, fresh-frozen tissue, 
stained or unstained tissues Figure 13. Limitations include the lack of a coverslip, which may 
cause difficulties in the recognition of histological features of some organs. The user may 
also experience difficulties when catapulting the area of interest into the collecting tube. This 
could be caused by too low laser power, too thick a section or incomplete tissue dehydration. 
In Study V, snap frozen tissue was sectioned using a cryostat, stained and reviewed for 
presence of DAC. If sufficient tumor volume, sections were cut and placed on membrane 
slides and underwent standard staining protocol with H&E. The tissue was then dehydrated 
before using the PALM Microbeam (Carl Zeiss MicroImaging, Bernried, Germany) for LCM 
and collection of tumor cells.  
 
Figure 13 Demonstrating a DAC case during laser capture microdissection, the holes seen in the central part of 
the picture shows the appearance of the tissue after the areas of interest have been dissected and catapulted into 
the collecting tube. 
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3.6 GENETIC STUDIES 
In Study V after the collection of tumor cells, DNA was extracted using the AllPrep 
DNA/RNA Mini Kit (Qiagen, Venlo, Netherlands), the kit allowing high-quality DNA to be 
used for downstream analysis. DNA was used for library preparation with ThruPlex FD kit 
(Rubicon Genomics, Ann Arbor, USA) creating indexed libraries through end repair, adapter 
ligation and high-fidelity library amplification.  
Recent advances make it possible to catalog genetic variations, thus creating a foundation for 
the understanding of prostate cancer. Sanger sequencing was described in 1977 and has since 
become the gold standard for DNA sequencing (133). Whole-genome sequencing is a 
comprehensive method for analysis of the genome and allows further downstream analysis 
when needed. Low-pass whole genome sequencing was used to determine copy number 
alterations in all cases using the Illumina platform (Illumina, San Diego, USA). Reads were 
aligned to a reference genome using Burrows-Wheeler Aligner (134) and quality controlled 
using the Picard software (Broad Institute, Cambridge, USA) (135). Copy number alterations 
were called from low-pass wgs data using Vardict (136) and variants annotated through the 
use of SndEff (137).  
3.7 STATISTICAL ANALYSIS 
Statistical analysis was performed using R statistics software (The R Project for Statistical 
Computing, Vienna, Austria) or SPSS (IBM SPSS Statistics for Macintosh, Version 22.0, 
Armonk, NY: IBM Corp). Univariate and multivariate Cox regression models were used for 
analyses of time to biochemical recurrence and Kaplan-Meier curves and log-rank test to 
compare biochemical recurrence-free survival between groups. The Chi-square test was used 
in Study I to IV for comparison of categorical variables between different groups while the 
unpaired t-test was used in Study III and IV to compare numerical variables between 
different groups. Fisher’s exact test was used in Study IV to compare differences in groups of 
small sample size. The predictive performance of explored markers in Study III was assessed 
by the area under the receiver operating characteristic (ROC) curve (AUC). In Study II 
interobserver variability was estimated by the use of pairwise unweighted kappa statistics. In 
all studies, p-values of less than 0.05 were considered significant.  
3.8 ETHICAL CONSIDERATIONS 
Study I-V were approved by the Regional Ethic Review Board, Stockholm (2006/1014-31, 
2013/1451-32, 2010/710-31/2) and the Aquesta Ethics Committee, Brisbane, Australia 
(AQ376421). 
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4 RESULTS AND DISCUSSION 
“A problem is a chance for you to do your best” 
     —Duke Ellington 
4.1 PAPER I: DAC IS MORE AGGRESSIVE THAN ACINAR 
ADENOCARCINOMA 
The aim of our first study was to retrospectively review RP specimens from Karolinska 
University Hospital to identify cases with a DAC component. Histological variants of DAC 
and their histopathological features were to be correlated with biochemical recurrence as little 
is known about the contributing factors to the poor prognosis of DAC. Hence, the aggressive 
clinical behavior of DAC makes it important to accurately define and diagnose this subtype. 
Of 1,051 sections reviewed, 86 (8.2 %) had a ductal component, two of these were pure DAC 
(2.3 %). Hence, pure DAC accounted for 0.2 % (2/1051) of all specimens reviewed. All other 
cases were mixed with acinar adenocarcinoma, which supports earlier reports that a majority 
of DAC are associated with acinar adenocarcinoma. The acinar component is often of high 
GS, which was true also in our study (35). A reason for the high prevalence of DAC cases is 
that these were identified by central review and not by database search, which is commonly 
used by other authors. Although studies have shown that DAC patients present at an older age 
(17, 36, 37), the mean age in the DAC and the acinar group at time of diagnosis was similar 
(64 and 62.3 years) as well as the preoperative s-PSA, which was 9.8 ng/ml and 8.2 ng/ml, 
respectively. s-PSA is not reliable for risk stratification of patients with DAC and has not 
been shown to correlate with clinical outcome (17).  
DAC tumors originated mainly from the PZ, a fact that seemed improbable at the time of 
discovery of DAC as it was thought that the tumors only arose in the periurethral ducts and 
the prostatic utricle (16). However, some DAC tumors are identified on cystoscopy as an 
exophytic growth into the urethra (24, 33). A majority of our cases (56.9 %) were diagnosed 
with palpable disease (T2), which is more than expected in a series of RP specimens and 
consistent with previous studies (35). Similar to the study of Christensen et al. (17), positive 
surgical margins, EPE and SVI were more common in DAC than in acinar adenocarcinomas. 
The most common architecture was a mixture of papillary and cribriform growth patterns.  
DAC is diagnosed on morphology alone and we attempted to classify potential DAC cases 
into subgroups and run statistical analyses to investigate the prognostic significance of 
histopathological features. The cases were divided into three groups as described in the 
material and methods section based on their resemblance to a classic DAC; DACC, DACB 
and PCDF Figure 14. The outcome data showed that DACC and DACB had similar hazard 
ratio and relapse rate while PCDF, hence cases with only stratified high-grade nuclei should 
not be classified as DAC. This is the first study attempting to describe a group with vague 
ductal features.  
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In line with other studies our results suggest that DAC has a worse prognosis than acinar 
adenocarcinoma although statistical significance was not reached, likely due to a low number 
of cases Figure 15. However, when biochemical recurrence was defined as a PSA of equal to 
or >0.5 ng/ml instead of 0.2 ng/ml, statistical significance was reached. A possible 
explanation for the results seen at this value is poor surgical techniques at the time of case 
collection when prostatic tissue may have been left in the resection area, thus secreting PSA 
and contributing to false-positive biochemical recurrence. 
In summary, DAC should be defined as a cancer with tall, columnar, pseudostratified 
epithelium, elongated or oval nuclei and/or papillary, glandular or cribriform architecture. 
Patients are more likely to present with EPE, SVI and positive surgical margins. We could 
not show that necrosis, stromal invasion versus intraductal spread, percentage of DAC 
component or localization within the prostate have any clinical significance. DAC is likely to 
be more aggressive than acinar adenocarcinoma, which is seen when biochemical recurrence 
is defined as a s-PSA of >0.5 ng/ml. 
The combination of DAC and acinar adenocarcinoma is commonly reported in the literature, 
likely because of underrepresenting as well as unclear diagnostic criteria. As the diagnosis of 
DAC is complicated by a wide spectrum of differential diagnoses such as HGPIN, IDC-P, 
pseudohyperplastic adenocarcinoma, urothelial carcinoma, colorectal adenocarcinoma and 
benign prostatic polyps, establishment of diagnostic criteria would facilitate diagnosis.  
 
Figure 14 Kaplan-Meier curve showing the survival probability for ductal versus acinar adenocarcinoma. Seipel 
et al. 2013 
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Figure 15 A) Ductal adenocarcinoma, classical type (DACC) with papillary architecture, tall, columnar 
epithelium with stratified nuclei with high-grade features. Hematoxylin and eosin, H&E, 10x lens magnification 
B) DACC with cribriform, invasive glands also showing a tall, columnar epithelium with stratified, high-grade 
nuclei. H&E, 10x C) DACC with papillary architecture, tall, columnar epithelium with crowded, stratified 
nuclei. H&E, 10x D) Same DACC case as in c showing papillary fronds with stromal cores, crowded, stratified 
nuclei with high-grade features. H&E, 20x E) Ductal adenocarcinoma, borderline type (DACB). The lining 
epithelium is columnar and branching but the nuclear features are more bland than in DACC and nuclei are 
rounded. H&E, 10x F) Prostatic carcinoma with ductal features (PCDF). The glands are lined with epithelium 
with stratified high-grade nuclei but the typical architecture of DACC is missing and the nuclei are not 
elongated. H&E, 20x. Seipel et al. 2013  
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4.2 PAPER II: PAPILLARY ARCHITECTURE IS THE MOST USEFUL 
DIAGNOSTIC FEATURE OF DAC WHILE NUCLEAR AND 
CELLULAR FEATURES ARE CONSIDERED LESS IMPORTANT 
Twenty expert uropathologists from over the world were asked to participate in our second 
study aiming to define diagnostic criteria for DAC. Two of these did not consider DAC to be 
a histological subtype but merely a variant of acinar adenocarcinoma and were therefore 
excluded from analyses.  
A set of six photomicrographs; three at 10x and three at 20x lens magnification were 
distributed using a web-based survey tool. These were all DACC and DACB cases from 
Study I. There was a 2/3 consensus for a DAC diagnosis in 11/21 (52 %) cases and consensus 
against DAC in 5/21 (24 %) cases. For the eleven consensus cases of DAC, papillary 
architecture was reported as the most important histopathological feature for diagnosing DAC 
followed by elongated nuclei, cribriform architecture, stratification of nuclei, tall columnar 
epithelium and high-grade nuclear features Figure 16. For the five cases with consensus 
against DAC, suggested diagnoses were acinar adenocarcinoma, IDC-P, HGPIN, 
pseudohyperplastic adenocarcinoma and PIN-like cancer. Some of the cases are displayed in 
Figure 17. 
IDC-P was the most frequently reported differential diagnosis and is notoriously difficult to 
separate from DAC. IDC-P, however, is an intraductal extension of high-grade acinar 
adenocarcinoma, hence cuboidal or low columnar cells with round nuclei and not the tall 
columnar epithelium seen in DAC. Nevertheless, the distinction is not always obvious. A 
cribriform DAC is composed of columnar epithelium with intraepithelial bridging and slit-
like lumina, while the lumina in IDC-P are typically rounded with a “punched out” 
appearance (85). To make matters even more confusing, we distinguish between intraductal 
spread of ductal adenocarcinoma and IDC-P, which represents intraductal spread of acinar 
adenocarcinoma. There is obviously still a need for better distinction between these two 
entities as morphological features may be shared between them. Two helpful features to 
distinguish between the two types are the papillary fronds with true fibrovascular stalks and 
the elongated nuclei that are seen in DAC but not in IDC-P.  
The second most common differential diagnosis was HGPIN, however, this is not as difficult 
to separate from DAC as IDC-P but distinction is critical for patient management and 
outcome. Micropapillary formations may be seen in HGPIN but they lack the true 
fibrovascular stalks seen in DAC. The size of the glands in HGPIN is similar to that of benign 
glands. Their spatial distribution is almost normal while the glands in DAC are often arranged 
back-to-back and enlarged. Comedonecrosis may also be seen in DAC (19). One can also 
look for mitotic activity, perineural invasion and hemosiderin deposition to separate DAC 
from HGPIN (99). In summary, HGPIN shows a less complex architecture than DAC, the 
nuclear atypia is not as high grade and papillary fronds with true fibrovascular stalks are not 
seen.  
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The distinction between DAC and acinar adenocarcinomas may be complicated as they 
typically co-exist and the histopathological features may overlap. However, small gland 
patterns are commonly seen in acinar adenocarcinomas while DAC is a large-gland 
adenocarcinoma. Acinar adenocarcinoma may have columnar epithelium and nuclear 
stratification, while DAC may present with rounded nuclei. They can both show intraluminal 
necrosis, cribriform patterns and high-grade nuclear features. As the acinar component is 
often of high GS in mixed tumors, the clinical implication of separating a GS 8 tumor with or 
without a DAC component does not affect patient management today, but it may very well be 
that patients with DAC should be treated aggressively considering the poor prognosis 
compared to acinar adenocarcinomas. However, it has been suggested that a DAC component 
of less than 10 % does not affect outcome (85).  
It is, however, important to separate pseudohyperplastic carcinoma and PIN-like carcinoma 
from DAC as they are considered Gleason pattern 3, reflecting their less aggressive behavior. 
Pseudohyperplastic carcinoma and DAC share the tall, columnar epithelium but the nuclear 
atypia and stratification are less conspicuous in pseudohyperplastic carcinoma. PIN-like 
carcinoma shows less nuclear atypia than DAC and has a less complex architecture.  
Lack of typical architecture was the most common reason to reject a DAC diagnosis. Other 
reasons were round nuclei, lack of nuclear stratification, only a limited amount of DAC 
present and the absence of true papillae. Or as one participant wrote, the tumor simply did not 
look nasty enough. The architecture was also the most helpful feature for establishing a DAC 
diagnosis.  
The multirater kappa value was a mere 0.23, pointing to the difficulties in diagnosing DAC 
and also the need for standardized criteria. Our study shows that the subtype of DAC is not as 
well defined as previously thought. The diagnosis of DAC is important for patient 
management as it has a poor prognosis but also for research purposes as the tumor is rare and 
there are few studies on larger materials. As histological subtypes other than acinar 
adenocarcinomas are unusual and account for less than 10 % of all prostate carcinomas, 
diagnosis is a clinical challenge. The disease specific mortality for DAC has been reported at 
12 % compared to 4 % for patients with acinar adenocarcinomas (18). This implies that a 
prostate cancer showing any component of DAC should be treated as high-risk disease owing 
to its potential to progress and metastasize (49).  
One could argue that five cases defined and analyzed as DACC and DACB in Study I were 
not diagnosed as DAC by the group of international pathologists in Study II. Hence, this may 
have affected the results of Study I as some of the cases should not be grouped and analyzed 
as DAC. Nevertheless, DAC has proved to be a challenging diagnosis with poor 
reproducibility even among some of the most experienced uropathologists worldwide and for 
all cases in this study, there were always one one more participants diagnosing the case as 
DAC even though the majority classified the case as something else. The results were 
expected for a tumor with poorly defined morphology and emphasize the need for 
standardized diagnostic criteria.  
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In summary, the finding of papillary architecture in combination with stratified nuclei 
supports a DAC diagnosis but needs to be correlated with outcome data in larger datasets.  
 
          
A                 B 
  
C 
Figure 16 Venn diagrams illustrating combinations of features in ductal adenocarcinomas. A) In 99 % papillary 
architecture (P), stratification of nuclei (S) or elongated nuclei was seen. P and S were combined in 68 % of 
cases. B) In 44 % P was combined with elongated nuclei C) In 41 % a combination of P, S and high-grade 
features (HG) was seen. Seipel et al. 2014 
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Figure 17 A) Consensus for ductal adenocarcinoma (DAC). Glandular pattern, pseudostratified epithelium with 
tall columnar cells and abundant cytoplasm. Nuclei are elongated with high-grade features. Hematoxylin and 
eosin, H&E, 20x lens magnification B) Consensus for DAC. Solid pattern and high-grade nuclear features. 
H&E, 10x C) Consensus against DAC. IDC-P lacking the tall, columnar epithelium seen in DAC. Rounded 
nuclei are seen H&E, 10x D) Consensus against DAC. IDC-P lacking the tall, columnar epithelium seen in 
DAC. Rounded nuclei are seen. H&E, 20x E) Consensus against DAC. HGPIN with less complex architecture 
than typically seen in DAC. Nuclear features are not as high grade. H&E, 20x F) Consensus against DAC. 
Acinar adenocarcinoma with small gland pattern. H&E, 10x. Seipel et al. 2014  
 
  46 
4.3 PAPER III: DAC SHOWS A MORE AGGRESSIVE PHENOTYPE 
THAN ACINAR ADENOCARCINOMA 
Few studies have examined the immunohistochemical features of DAC compared to acinar 
adenocarcinoma, even though DAC is considered more aggressive and the diagnosis is based 
on morphology alone (58, 138, 139). IHC is routinely used for the diagnosis of acinar 
adenocarcinoma and efforts have been made to identify antibodies of prognostic significance 
(140). We aimed to examine several types of markers including prostate-specific markers, 
cell-cycle related markers, oncogenes, hormones and hormonal receptors, cytokeratins and 
intestinal markers. To correctly identify subtypes of prostate cancer is important as clinical 
behavior varies according to morphotype.  
Prostate specific markers were chosen as a patchy PSA positivity is sometimes seen in DAC 
and there have even been reports on PSA negative cases (21, 54). Hormone receptors were 
added because of the presumed origin of DAC, a Müllerian tissue rest, hence a female tissue, 
which should stain positive for estrogen receptor. Intestinal markers were included as DAC 
may mimic a gastrointestinal adenocarcinoma. Ki-67 was included as DAC seem to behave 
more aggressively than matched acinar adenocarcinoma and we wanted to investigate 
whether this was also reflected in the proliferation index. For the same reason several cell-
cycle specific markers were also added. We hypothesized that cytokeratin expression may 
differ in DAC tumors located close to the urethra due to the gradual change from the 
CK7/CK20 negative acinar adenocarcinoma of the prostate to the CK7/CK20 positive 
urothelium. 
In a TMA 60 DAC cases were matched by GS against 46 acinar adenocarcinomas and stained 
with immunomarkers. Five out of 28 markers were differentially expressed in DAC vs. acinar 
adenocarcinoma; HMWCK, p16, Ki-67, CK20 and p53 Figure 18. Of the intestinal markers, 
CEA was positive in one DAC case and villin in two.  
Acinar adenocarcinoma is typically PSA and PSAP positive, CK7/CK20 negative and does 
not stain for basal cell markers such as p63 or HMWCK (58). PSA staining may be weak or 
patchy in specimens of high GS (61, 141) and may be weak, focal or completely negative in 
DAC. A distinct focal CK20 staining was observed more often in DAC than in acinar 
adenocarcinomas. There are descriptions of CK20 staining in acinar adenocarcinomas of high 
GS but more than 50 % staining is rarely seen (61). The hormone receptor status of DAC was 
similar to that of acinar adenocarcinoma. Three markers support the more aggressive nature 
of DAC compared to acinar adenocarcinomas; Ki-67, p16 and p53. Several papers have 
suggested Ki-67 as an independent prognostic marker (142, 143). We found that DAC had a 
higher labeling index than grade matched acinar adenocarcinomas with a mean labeling index 
of 9.2 % and 2.6 %, respectively (p=<0.001). This supports findings in previous studies and 
the view that DAC is an aggressive subtype. p16 is a tumor suppressor protein inhibiting the 
interaction between cyclin D1 and CDK 4 or 6, thus leaving the cell in G1 arrest. It is thought 
to play a role in cancer progression, poor outcome and tumor recurrence (144, 145).  
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The debate of whether to call DAC a distinct subtype of prostate cancer or merely a variant of 
acinar adenocarcinoma is ongoing, however, our study supports the view of DAC as an 
aggressive subtype, supported by the expression of Ki-67, p53 and p16 and its unique 
morphological features.  
 
Figure 18 A) Ductal adenocarcinoma of the prostate with papillary architecture and tall, columnar epithelium. 
Hematoxylin and eosin, 10x lens magnification B) DAC stained with Ki-67 showing high labeling index. H&E, 
20x C) DAC stained with CK20 showing a patchy positive staining pattern. H&E 20x D) Acinar 
adenocarcinoma stained with CK20 also showing a patchy positive staining. H&E 20x E) DAC stained with p16. 
H&E 20x F) DAC stained with villin, one of two positive cases. H&E 20x. Seipel et al. 2014 
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4.4 PAPER IV: PROSTATE SPECIFIC MARKERS SHOULD BE 
ADDED IN MEN WITH ADENOCARCINOMAS OF UNKNOWN 
ORIGIN EVEN IF THE TUMOR MORPHOLOGY SUGGESTS A 
NON-PROSTATIC ORIGIN 
To diagnose the site of origin of a metastatic adenocarcinoma has clinical implications as 
today’s cancer therapies are increasingly organ specific. IHC is a cheap diagnostic tool 
compared to radiology, surgical procedures or endoscopy as these modalities are not only 
expensive but time-consuming, inconvenient and may be unsuccessful (146). IHC and 
histopathologic examination are the key to optimal patient management as they shorten time 
to diagnosis while at the same time being cost-effective (147). Our aim was to compare DAC 
to adenocarcinomas of other origin and suggest a use of IHC to establish the tissue origin at a 
metastatic site. Although endometrial adenocarcinoma is not a differential diagnosis to 
prostate cancer it was included because of the historical presumed origin of DAC from 
Müllerian duct remnants (16).  
While metastases from prostate cancer are typically seen in lymph nodes, bone, lung, liver, 
pleura and adrenals, DAC also metastasizes to unusual locations such as the testis and penis 
(92, 93, 148, 149). When encountered at a metastatic site, DAC tumors may resemble 
adenocarcinomas of non-prostatic origin, thus making diagnosis challenging. Colorectal 
cancers may also extend directly into the prostate, mimicking DAC by also displaying tall, 
columnar epithelium and complex glands (150, 151). A combination of prostate specific 
markers and intestinal markers is preferably used for diagnosis, including CDX2, villin and 
β-catenin (97). We found all colorectal adenocarcinomas and nine DAC to be CDX2 positive 
and two DAC cases also stained positively for villin. However, all colonic adenocarcinomas 
were negative for all prostate specific markers. Separating DAC from colorectal 
adenocarcinoma may not only be difficult in the prostate but also in the lung, DAC in fact 
being the second most common type of prostate cancer metastasizing to the lung (91). A plot 
showing the proportion of staining for each individual organ is seen in Figure 19. 
Adenocarcinomas of the urinary bladder are best identified using a combination of markers 
such as GATA3, CK20, p63 and HMWCK (152). We noted overlap in CK20 staining while 
p63 was negative in all DAC cases but positive in a majority of urothelial adenocarcinomas. 
HMWCK was less often expressed in DAC than in urothelial cancer. Nevertheless, there is an 
overlap between the two types and prostate-specific markers as well as GATA3 should be 
added to determine the site of origin.  
Our study supports previous studies claiming DAC to be a tumor of prostatic origin, staining 
negatively for ER, PAX-8 and progesterone receptor and positively for prostate specific 
markers PSA, PSAP and prostein (24, 52). The International Society of Urologic Pathology 
(ISUP) recommend combinations of markers to establish tissue origin and recommend a 
combination of PSA, PSAP, prostein and NKX3.1 to establish a prostatic origin (97).  
   49 
Although we have shown that DAC has a higher Ki-67 labeling index than grade matched 
acinar adenocarcinomas, it was still lower than in other adenocarcinomas included in our 
study. There were overlap between tumor types but a high proliferation rate may be useful to 
distinguish DAC from adenocarcinomas of non-prostatic origin.  
A limitation of our study is that few cases of each tissue type were included, which may have 
affected the power to detect differences between the organs. Biopsies from metastatic DAC 
are rare so all tissues were harvested from primary tumors. As we used primary tumor tissue 
from DAC, we also used primary tissue from the other organs.  
In summary, the combination of prostate specific markers PSA, PSAP and prostein likely 
confirms the prostatic origin. In men with cancer of unknown origin the threshold for 
applying prostate specific stains to verify a possible prostatic origin should be low, even 
when the morphology suggests that the tumor is non-prostatic. 
 
Figure 19 Plot showing the proportion of positive staining presented by marker and individual organ. Seipel et 
al. 2016 
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4.5 PAPER V: THE GENETIC PROFILE OF DAC IS SIMILAR TO 
THAT OF ADVANCED AND METASTATIC PROSTATE CANCER 
Despite the recent progress and diminishing cost of whole genome sequencing, little is known 
about the genetic profile of DAC compared to acinar adenocarcinomas. Understanding the 
different geno- and phenotypes of prostate cancer is crucial as we move towards personalized 
cancer medicine.  
We aimed to examine the genetic profile of DAC in search for genetic properties accounting 
for its aggressive biological behavior. DNA was sequenced using low-pass sequencing for 
copy-number alterations (CNA), mutations and indels. We also compared the fraction of 
genome affected by copy-number alterations in DAC to primary acinar adenocarcinomas, as 
the fraction of affected genome is associated with poor prognosis (153, 154). We found that 
the fraction of genome affected by CNA in DAC was similar to that of GS 8-9 tumors Figure 
20. The genetic alterations varied in the eleven cases, some showing several genetic 
alterations while others showed alterations in single genes only Figure 21.  
Two DAC cases had frameshift indels in APC, two had TP53 mutations and two had FOXA1 
mutations. FOXA1 is a member of the AR signaling pathway, which is often disrupted in 
prostate cancer and a main therapeutic target. The signaling pathway may be disrupted in AR 
itself but commonly through members of the pathway such as FOXA1 or SPOP. SPOP 
mutations are possible driver events in prostate cancer and are seen in both localized and 
metastasized prostate cancer (68). If mutated, FOXA1 represses androgen signaling, thus 
promoting tumor growth (77).  
Prostate cancers may be classified into genetically different subgroups defined by mutations 
in SPOP, FOXA1, IDH1 and ETS fusions to name a few (155). The ETS transcription factor 
family is well known in prostate cancer, primarily through the well known TMPRSS2-ERG 
fusion (70). Other members include ETV1 and ETV5, both associated with metastatic disease 
and described as clonal events in prostate cancer (156). We identified two cases with ETV1 
and/or ETV5 amplifications. Interestingly, ETS rearranged tumors may also show lesions in 
the PI3K and TP53 signaling pathways, which was observed in four of our cases.  
TP53 is the most commonly mutated gene in all human cancers (84). One case showed a 
germline mutation in BRCA2, which is associated with the highest risk of developing 
prostate cancer known to date (157). Copy-number altered genes included deletions in APC, 
CHD1 and HDAC2, results that may be associated with treatment response to PARP 
inhibitors (158).  
ERG negativity is more common in DAC than in acinar adenocarcinomas (75, 159) and is 
linked to MAP3K deletions, MAP3K acting as a tumor suppressor in prostate cancer (160). 
Deletions are associated with early biochemical recurrence, advanced tumor stage, lymph 
node metastases and a high GS, all are features seen in DAC (114). Also common in 
metastatic tumors are CHD1 deletions, which were also seen in two of our DAC cases (77, 
84).  
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Other alterations supporting the aggressive behavior of DAC tumors are BDH1 
amplifications associated with a high GS and androgen independent prostate cancers (161), 
knock-down of SMYD3 attenuating the malignant phenotype of prostate cancer (162), 
expression of genes associated with epithelial to mesenchymal transition such as PTPRN2, 
facilitating spread of cancer cells (163) and alterations in tumor suppressor APC, altering the 
Wnt pathway (164).  
In summary, our study shows that DAC has a genetic profile similar to that of advanced 
and/or metastatic prostate cancer and gives a possible genetic explanation for the aggressive 
biological behavior. 
 
Figure 20 Fraction of the genome altered by copy-number alterations. Y-axis; fraction of the genome altered. X-
axis; Gleason score 5-9 acinar adenocarcinomas and the eleven ductal adenocarcinomas. Seipel et al. 2016 
 
Figure 21 (as seen on next page): Genes affected by mutations and copy-number alterations. Genes were 
grouped according to the core pathway affected. In instances with few genes assigned to individual pathways, 
data were aggregated into larger groups. Y-axis; gene names. X-axis; individual tumor IDs. Mutational data is 
missing from DUCTAL22830, DUCTAL28255, DUCTAL25664, DUCTAL20607 due to low library 
complexity. Seipel et al. 2016 
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5 CONCLUDING REMARKS 
DAC is more aggressive than acinar adenocarcinoma when defined as a tumor with tall, 
columnar epithelium with stratified, elongated or oval, high-grade nuclei and a papillary, 
cribriform and/or glandular architecture. Cancers with only stratified, high-grade nuclei 
should not be considered DAC. Patients with DAC are more likely to present with 
extraprostatic extension, positive surgical margins and seminal vesicle invasion. Necrosis, 
stromal invasion versus intraductal spread, percentage of DAC tumor or localization does not 
seem to have clinical significance.  
The diagnosis of DAC is not as well-defined as previously thought. Papillary architecture in 
combination with nuclear stratification support the diagnosis, while nuclear and cellular 
features are less important. The most common differential diagnoses to DAC are IDC-P and 
HGPIN.  
There is some overlap in the immunohistochemical expression of DAC and acinar 
adenocarcinoma. However, DAC shows greater expression of Ki-67, p53 and p16 than acinar 
adenocarcinoma and the differences between these subtypes are consistent with DAC being 
biologically more aggressive. 
The combination of prostate specific markers PSA, PSAP and prostein likely confirms the 
prostatic origin of a DAC tumor if encountered in a metastatic deposit. In men with cancer of 
unknown origin, the threshold for applying prostate specific stains to verify a prostatic origin 
should be low, even when the morphology suggests that the tumor is in fact non-prostatic. 
The genetic profile of DAC is similar to that of advanced and/or metastasized prostate cancer, 
which may explain its aggressive biological behavior.  
Immunohistochemistry, morphological features, clinical course and genetic profile all support 
the current view of DAC as a distinct clinical entity.  
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